Abstract
Aim: Percutaneous mitral valve repair (PMVR) with MitraClip® has proven to be an effective therapy to reduce mitral regurgitation in patients at high risk for conventional surgery. This population is currently characterized by advance age and high prevalence of comorbidities. Our aim was to evaluate the prevalence of frailty in a cohort of patients undergoing PMVR and its impact on clinical outcomes during follow-up.
Highlights
In the last decade, percutaneous mitral valve repair (PMVR) with MitraClip® device (Abbot Vascular, Santa Clara, USA) has proven to be an effective therapy to reduce mitral regurgitation (MR), with a low incidence of complications in patients deemed as high-risk candidates or unfit for conventional surgery[1]
Frailty was common in patients undergoing PMVR in our institution
Despite post-procedural clinical improvement, frailty was related to adverse outcomes in our series
Summary
Percutaneous mitral valve repair (PMVR) with MitraClip® device (Abbot Vascular, Santa Clara, USA) has proven to be an effective therapy to reduce mitral regurgitation (MR), with a low incidence of complications in patients deemed as high-risk candidates or unfit for conventional surgery[1]. Risk stratification in these patients is challenging and it is usually based on non-dedicated risk scores developed in the surgery field, with a modest predictive value in this scenario[2]. The main objective of our study was to assess the prevalence of frailty in a cohort of patients undergoing PMVR, and to assess its impact on clinical outcomes during follow-up
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have